Health Canada has sharply tightened its gatekeeping of psilocybin for treatment-resistant depression, doubling refusal rates from 21% (2022) to 43% (2024) and drawing criticism for an opaque approval process. Read the full story
—
Health Canada is now severely restricting access to psilocybin for treatment-resistant depression, with refusal rates rising from 21% in 2022 to 43% in 2024, prompting criticism that the process is opaque. Read the full article .